-+ 0.00%
-+ 0.00%
-+ 0.00%

Idorsia's Oral Hypertension Treatment Lands Marketing Approval in Canada

MT Newswires·01/05/2026 01:28:17
Listen to the news
01:28 AM EST, 01/05/2026 (MT Newswires) -- Idorsia (IDIA.SW) said Monday it secured Health Canada's marketing authorization for Jeraygo, or aprocitentan, to treat adults with resistant hypertension. The approval allows the use of the oral antihypertensive therapy in combination with at least three antihypertensive medicinal products, at a recommended dose of 12.5 milligrams once a day, or 25 mg per day for patients tolerant to the 12.5 mg dose. The biopharmaceutical company is currently in talks with potential partners to boost Jeraygo's marketing.